We are live on ! Find out more
Ken Griffin

Ken Griffin Citadel Advisors

AUM $875B
1-Year Est. Return 40.91%
 

Ken Griffin founded Citadel, one of the world’s largest and most successful hedge funds. Starting his trading career from his Harvard dorm room at a young age, Griffin quickly developed a keen sense for markets and built Citadel into a global powerhouse with billions in assets under management. Known for his quantitative and technology-driven strategies, Griffin has also made headlines for significant philanthropic contributions, supporting causes in education, the arts, and public institutions. Over the years, he has earned recognition as one of the preeminent figures in modern finance.

This Fund
S&P 500
This Quarter Est. Return
-1.06%
1 Year Est. Return
+40.91%
3 Year Est. Return
+115.85%
5 Year Est. Return
+132.1%
10 Year Est. Return
+518.81%
AUM
$481B
AUM Growth
+$34.6B
Cap. Flow
+$38.1B
Cap. Flow %
7.92%
Top 10 Hldgs %
29.35%
Holding
15,428
New
1,885
Increased
5,794
Reduced
5,768
Closed
1,724

Top Buys

Rank Stock Value
1
TSLA icon
Tesla
TSLA
+$1.26B
2
MSFT icon
Microsoft
MSFT
+$633M
3
BABA icon
Alibaba
BABA
+$501M
4
ATVI
Activision Blizzard
ATVI
+$484M
5
AAPL icon
Apple
AAPL
+$456M

Top Sells

Rank Stock Value
1
META icon
Meta Platforms (Facebook)
META
+$622M
2
ALXN
Alexion Pharmaceuticals
ALXN
+$597M
3
CMCSA icon
Comcast
CMCSA
+$461M
4
UNH icon
UnitedHealth
UNH
+$409M
5
MXIM
Maxim Integrated Products
MXIM
+$343M

Sector Composition

Rank Sector Weight
1 Technology 3.08%
2 Consumer Discretionary 2.25%
3 Financials 2.23%
4 Healthcare 2.22%
5 Industrials 1.46%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CNCE
13151
CALL
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
$61K ﹤0.01%
18,800
-20,300
-52% -$71.1K
AMPE
13152
PUT
DELISTED
Ampio Pharmaceuticals Inc.
AMPE
$61K ﹤0.01%
122
+48
+65% +$22.3K
NAVB
13153
PUT
DELISTED
Navidea Biopharmaceuticals Inc.
NAVB
$61K ﹤0.01%
35,100
+3,700
+12% +$6.23K
CETX icon
13154
Cemtrex
CETX
$5.2M
– –
0
– –
CRVO icon
13155
CervoMed
CRVO
$36.9M
$60K ﹤0.01%
1,559
-456
-23% -$19K
HDSN
13156
Hudson Technologies
HDSN
$239M
$60K ﹤0.01%
17,103
-35,915
-68% -$120K
MIST icon
13157
Milestone Pharmaceuticals
MIST
$137M
$60K ﹤0.01%
+10,466
New +$59K
NEXT icon
13158
NextDecade
NEXT
$1.91B
$60K ﹤0.01%
+21,635
New +$68.2K
TGB
13159
CALL
Trekor Metals
TGB
$3.06B
$60K ﹤0.01%
31,900
+13,900
+77% +$25K
VYGR icon
13160
PUT
Voyager Therapeutics
VYGR
$201M
$60K ﹤0.01%
22,700
-110,800
-83% -$360K
YARW
13161
CALL
Yarrow Bioscience, Inc. Common Stock
YARW
$113M
$60K ﹤0.01%
48
+11
+30% +$21.3K
XFOR icon
13162
PUT
X4 Pharmaceuticals
XFOR
$418M
$60K ﹤0.01%
+377
New +$62K
IMBI
13163
CALL
DELISTED
iMedia Brands, Inc. Class A Common Stock
IMBI
$60K ﹤0.01%
+10,500
New +$67.4K
CTIC
13164
CALL
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
$60K ﹤0.01%
20,200
-11,000
-35% -$30K
JG
13165
PUT
Aurora Mobile
JG
$34.2M
$59K ﹤0.01%
1,755
-615
-26% -$27.5K
LGMK
13166
CALL
DELISTED
LogicMark
LGMK
$59K ﹤0.01%
29
-31
-52% -$105K
MYPS icon
13167
PUT
PLAYSTUDIOS Inc
MYPS
$63.1M
$59K ﹤0.01%
13,000
-4,800
-27% -$27K
SCOR icon
13168
PUT
Comscore
SCOR
$93.6M
$59K ﹤0.01%
750
-1,715
-70% -$136K
VNRX icon
13169
VolitionRx Ltd
VNRX
$6.47M
$59K ﹤0.01%
+954
New +$60.4K
WATT icon
13170
Energous
WATT
$85.6M
$59K ﹤0.01%
47
-16
-25% -$22.9K
TECX
13171
PUT
Tectonic Therapeutic
TECX
$682M
$59K ﹤0.01%
+883
New +$72.5K
FACA.WS
13172
DELISTED
Figure Acquisition Corp. I Redeemable warrants, each whole warrant exercisable for one share of Class A common stock at an exercise price of $11.50
FACA.WS
$59K ﹤0.01%
+56,427
New +$64K
TMBR
13173
DELISTED
Timber Pharmaceuticals, Inc.
TMBR
$59K ﹤0.01%
1,286
+754
+142% +$37K
LUB
13174
DELISTED
Luby's Inc.
LUB
$59K ﹤0.01%
+14,199
New +$57.8K
BFRA
13175
DELISTED
Biofrontera AG American Depositary Shares
BFRA
$59K ﹤0.01%
10,716
-2,475
-19% -$14.6K
525 526
527
528 529

Similar funds

Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

Ken Griffin's Q3 2021 Portfolio in Review

As of Q3 2021, Ken Griffin held 15,428 positions worth $481B, up 7.8% from $447B the previous quarter. Its ten largest holdings account for 29% of the portfolio.

Ken Griffin deployed $38.1B of net new capital in Q3 2021, opening 1,885 new positions and adding to 5,794 existing holdings. Its largest new stake was Etsy: 948,509 shares worth $197M.

By sector, the portfolio is most concentrated in Technology at 3.1% of assets, down from 3.2% a quarter earlier, followed by Consumer Discretionary and Financials.

On the sell side, the largest reduction was Meta Platforms (Facebook), an estimated $622M trimmed.

  • Ken Griffin's largest Q3 2021 buy was Etsy: 948,509 shares worth $197M.
  • Ken Griffin added most to Tesla in Q3 2021, an estimated $1.26B increase.
  • Ken Griffin's biggest Q3 2021 reduction was Meta Platforms (Facebook), cutting an estimated $622M.
  • Ken Griffin fully exited Alexion Pharmaceuticals in Q3 2021, selling an estimated $597M.
  • Ken Griffin's ten largest holdings make up 29% of its $481B portfolio in Q3 2021.
  • Ken Griffin opened 1,885 new positions and closed 1,724 in Q3 2021.
  • Ken Griffin's portfolio value rose 7.8% quarter-over-quarter to $481B.

Based on Citadel Advisors's 13F filing for Q3 2021, filed 15 Nov 2021.